Doctor Pharmaceuticae - Dpharm / Among neurological disorders, many of the most devastating disorders are neurodegenerative. Modern research associates excitotoxicity to a variety of neuropathological conditions, suggesting that the neurodegenerative diseases with distinct etiologies may have excitotoxicity as a common pathway. Excitotoxicity occurs through over-stimulation of receptors for excitatory neurotransmitters like the N-methyl-D-aspartate (NMDA) receptors. Due to the relevance of NMDA receptors and excitotoxic processes, the antagonism or modulation of NMDA receptors is used as a therapeutic tool against neurodegenerative diseases. NMDA receptor activity can be modulated by S-nitrosylation and this modulation of NMDA receptor activity can be utilised in the development of neuroprotective drugs.

Dysfunction of the N-methyl-D-aspartate (NMDA) receptor is thought to contribute to the cognitive deficits of many neurodegenerative diseases and psychiatric disorders. Cognitive symptoms of Alzheimer's disease can be treated with NMDA receptor antagonists or drugs targeting the cholinergic system; however, there are no effective treatments for cognitive deficits of schizophrenia or Huntington's disease. With the discovery of a potent and selective allosteric modulator of the NMDA receptor, there is the possibility of new treatments based on NMDA receptor functional-enhancement through neuroactive steroids, closely related in structure to the endogenous neurosteroid, cerebrosterol. The aim of this thesis was to examine steroidal modulation of the NMDA receptor both in vitro and in vivo. In chapter 2, NMDA receptor enhancement of both the synthetic and endogenous neuroactive steroids was assessed in neurons maintained in cell culture using calcium imaging techniques. Sulphation of the steroids greatly increased the efficacy of NMDA receptor enhancement compared to the unsulphated steroids. Chapters 3 and 4 investigate the potential for neuroactive steroids to treat cognitive impairments of Huntington's disease. Using a mouse model, tests were selected that were analogous to those in which patients are impaired; however, no impairments were found in the mouse model. Chapter 5, therefore, used a different model of cognitive impairment – namely, rats with a set-shifting impairment, as is seen in many psychiatric and neurological disorders, including Huntington's disease – to assess the effect of the synthetic steroid administration. Unfortunately, the rats did not show the expected impairment. The lack of reliable animal models compromised testing the efficacy of these promising NMDA receptor positive allosteric modulators. Nevertheless, the promising in vitro results suggest that there could still be therapeutic potential. In addition, the compound is a useful research tool for exploring NMDA receptor function in health and disease.

Made available in DSpace on 2014-12-17T14:16:34Z (GMT). No. of bitstreams: 1 AnaLSAM_DISSERT.pdf: 1550415 bytes, checksum: caf1d01895bb5be79ca908c1ce3bf0f9 (MD5) Previous issue date: 2013-03-19 / Panax ginseng CA Meyer (Araliaceae) is a herbaceous plant widely used in China, South Korea, Japan and other Asian countries for the treatment of various diseases micro circulatory, cerebrovascular, among others, representing one of the drugs used by older man. It has over 30 biologically active ginsenosides with different pharmacological and behavioral effects and inhibitory effect on the NMDA receptor. The amino acid glycine is a co-agonist of the NMDA receptor, activating this receptor. At the cellular level, ketamine is widely known to be NMDA receptor antagonist. The aim of this study was to evaluate the general activity in the open field, and anxiety in elevated plus maze, mice treated with P. ginseng compared with the action of ketamine and glycine, to better understand the action of this herbal medicine at the NMDA receptor. We used 66 adult male rats were divided into six groups: a positive control, treated for 30 days with water by gavage, who received glycine (500mg/kg; po) on days 7, 14, 21 and 28 of treatment, one hour before of behavioral assessment, a negative control was treated for 30 days with water by gavage received ketamine (5mg/kg, ip) on days 7, 14, 21 and 28 of treatment, one hour prior to behavioral evaluation, three experimental groups, receiving 100, 200 or 300 mg / kg P. ginseng by gavage for 30 days and one group treated solely with white water, and is also administered 1 ml of water by gavage one hour prior to behavioral evaluation. Animal behavior in these three groups was also examined on days 7, 14, 21 and 28 of treatment. On day 30 of treatment, the animals were anesthetized with thiopental (70mg/kg) for blood collection and after euthanasia, withdrawal of various organs. There were no changes in weight and body weight gain and weight reasons in organ / body weight. However the consumption of water and food values showed a significant increase. Serum levels of AST was increased in a dose-dependently in the animals treated with doses of P. ginseng, glycine and ketamine as compared to the blank group. Unlike creatinine levels proved to be decreased in all treated groups when compared with white. However, the level of urea in these groups was reduced and no changes were observed in the ALT parameter. Histopathological examination revealed no changes in cell morphology in different tissues. There were no behavioral changes in the elevated plus maze and few changes were observed in the open field, animals treated with P. ginseng, glycine and ketamine when compared to white. These data suggest that the doses of P. ginseng employed were unable to induce general toxicity in rats treated for 30 days and also shows that the general behavior of mice treated with P. ginseng was slightly different from that observed in animals treated with ketamine and glycine. Finally, the study on the elevated plus maze showed that the extract of P. ginseng showed no anxiolytic or anxiogenic action / Panax ginseng C.A. Meyer (Araliaceae) ? uma planta herb?cea muito usada na China, Cor?ia do Sul, Jap?o e outros pa?ses da ?sia no tratamento de v?rias doen?as micro circulat?rias, vasculares cerebrais, entre outras. Possui mais de 30 ginsenos?deos, que inibem o receptor NMDA, provocando diferentes efeitos farmacol?gicos e comportamentais. O objetivo do presente estudo foi avaliar a atividade geral, no campo aberto, e a ansiedade, no labirinto em cruz elevado, de ratos tratados com P. ginseng. Ratos tratados com ketamina (antagonista do receptor NMDA) e com glicina (coagonista do receptor NMDA), foram tamb?m empregados para melhor entendimento do mecanismo de a??o desse fitoter?pico. Foram utilizados 66 ratos machos adultos, divididos em seis grupos: um controle positivo (n=12), tratado durante 30 dias com ?gua por gavagem, que recebeu glicina (500mg/kg; v.o.) nos dias 7, 14, 21 e 28 de tratamento, uma hora antes da avalia??o comportamental; um controle negativo (n=12), tratado durante 30 dias com ?gua por gavagem, que recebeu ketamina (5mg/kg; i.p.) nos dias 7, 14, 21 e 28 de tratamento, uma hora antes da avalia??o comportamental; tr?s grupos experimentais (n=12), que receberam 100, 200 ou 300 mg/kg de P. ginseng, por gavagem, durante 30 dias e um grupo branco (n=6) tratado exclusivamente com ?gua, sendo tamb?m administrado 1mL de ?gua por gavagem uma hora antes da avalia??o comportamental. O comportamento animal nesses grupos tamb?m foi analisado nos dias 7, 14, 21 e 28 de tratamento. No dia 30 de tratamento os animais foram anestesiados para coleta de sangue e retirada de ?rg?os diversos, que tiveram seus pesos anotados e por??es foram coletadas para estudo histopatol?gico. N?o foram observadas altera??es no peso e ganho de peso corporal entre os diversos grupos nem nas raz?es peso ?rg?o/peso corporal calculadas. Nos animais tratados com P. ginseng, ketamina e glicina o consumo de ?gua e de ra??o e as concentra??es s?ricas de AST revelaram estar aumentadas em compara??o com grupo branco. Entretanto, os animais tratados com as tr?s doses de P. ginseng, ketamina e glicina apresentaram n?veis reduzidos de creatinina e ureia quando comparados com o grupo branco. N?o foram observadas altera??es no par?metro ALT. O estudo histopatol?gico revelou aus?ncia de altera??es na morfologia celular nos diversos tecidos analisados. N?o foram encontradas altera??es comportamentais no labirinto em cruz elevado e poucas altera??es foram observadas nos animais tratados com P. ginseng, glicina e ketamina quando comparados com o grupo branco, no campo aberto. Esses dados sugerem que as doses de P. ginseng empregadas n?o foram capazes de provocar toxicidade geral em ratos tratados por 30 dias e revela tamb?m que o comportamento geral dos ratos tratados com P. ginseng foi pouco diferente daquele observado nos animais tratados com glicina e ketamina. Por fim, o estudo no labirinto em cruz elevado mostrou que o extrato de P. ginseng n?o apresentou a??o ansiog?nica nem ansiol?tica nas condi??es experimentais adotadas

Cognitive deficits are the single strongest predictor of the functional outcome in patients with schizophrenia. Current treatments are largely ineffective in improving cognitive impairments and promising pre-clinical research has mostly failed to translate clinically. Despite the advances provided by rodent models, the neurobiological basis of cognitive deficits in schizophrenia is poorly understood. Therefore, this thesis proposes a zebrafish model for studying cognitive impairments of schizophrenia. Although more evolutionarily distant to humans compared to the rat, the zebrafish has emerged as a popular vertebrate model of human disorders due to its genetic tractability, complex nervous system and elaborate behavioural repertoire. We investigated the effects of genetic alterations and neurodevelopmental disruption on behaviour and learning in zebrafish. Using both disc1 mutant lines and sub-chronic phencyclidine (PCP) on larvae from 6-10 dpf, we were able to assess behavioural changes as a function of developmental age. In particular, this thesis aimed to develop appropriate behavioural assays to assess zebrafish learning and executive function relevant to disorders seen in human patients with schizophrenia. It was possible to demonstrate robust learning across several domains, namely, reversal, classical avoidance and non-associative learning, alongside locomotor and anxiety-related behaviours. There were varied deficits associated with each of the two – genetic (disc1 gene mutation) and environmental (sub-chronic PCP) – manipulations, consistent with observations in rat research. Together, the research in this thesis demonstrates that a zebrafish model exhibits behaviour resembling that of mammalian models of schizophrenia and provides a foundation for the utility of zebrafish in examining cognitive impairments associated with schizophrenia.

Apprendre de nouvelles séquences d'actions est l'une des fonctions cruciales du système nerveux central. Cet apprentissage est notamment assuré par les ganglions de la base ;ceux-ci jouent un rôle critique dans la sélection d'actions ou la prise de décisions en permettant l'apprentissage et la sélection des programmes moteurs les plus appropriés. Comprendre la physiologie de cette circuiterie neuronale hautement complexe et particulièrement celle du striatum - structure d'entrée des ganglions de la base - est donc d'une importance capitale dans l'amélioration de notre compréhension de ce système neuronal. Dans ce travail, nous nous sommes intéressés au rôle fonctionnel du récepteur NMDA (NMDA-R) dans une sous-population des neurones de projection, les neurones striatopallidaux. Ces récepteurs sont impliqués dans les modifications de l'efficacité synaptique à long terme et jouent donc un rôle central dans le mécanisme d'apprentissage. Notre travail démontre que le NMDA-R des neurones striatopallidaux est un élément essentiel de l'apprentissage au niveau des ganglions de la base. En effet, nous observons que des souris transgéniques, déficientes en NMDA-R spécifiquement dans les neurones striatopallidaux, disposent d'une capacité d'adaptation réduite aux modifications de leur environnement. De plus, nous démontrons que ces souris transgéniques présentent des connexions neuronales affaiblies susceptibles d'expliquer les altérations comportementales observées. Dans ce travail de thèse, nous avons également développé une stratégie expérimentale reposant sur l'utilisation d'outils optogénétiques afin de déterminer le rôle d'une population d'interneurones inhibiteurs du striatum, les "fast spiking interneurons" (FSI). Cette technique a été mise en oeuvre avec succès et nous avons validé son efficacité in vitro. Nous démontrons que cette approche permet un contrôle l'activité électrique des FSI à l'échelle de la milliseconde. Son application in vivo, combinée avec des paradigmes comportementaux, nous permettra d'élucider le rôle spécifique de cette sous-population neuronale, tant au niveau du contrôle moteur que de la prise de décisions, dans des situations physiologiques ou pathologiques. Dans son ensemble, le présent travail ouvre les portes vers une meilleure compréhension de l'orchestration de la microcircuiterie striatale. / Doctorat en Sciences biomédicales et pharmaceutiques / info:eu-repo/semantics/nonPublished

A esquizofrenia é uma desordem neuropsiquiátrica de importância significativa para as pesquisas na área da saúde, porém, apesar de ser alvo de inúmeros estudos clínicos e básicos ainda são levantadas muitas dúvidas a respeito de sua etiologia, fisiopatologia e tratamento. Nos últimos anos, hipóteses que relacionam a esquizofrenia a alterações em sistemas neurotransmissores têm sido bem relevantes. Atualmente a hipótese glutamatérgica complementa a dopaminérgica, já que o bloqueio de receptores glutamatérgicos do tipo NMDA induz sintomas do tipo psicóticos em indivíduos saudáveis e exacerba ou precipita sintomas da esquizofrenia em indivíduos portadores da doença, sugerindo que um estado hipofuncional desses receptores possa causar alterações secundárias em outros sistemas neurotransmissores e provocar tanto os sintomas positivos e negativos quanto os déficits cognitivos da doença. O canabidiol (CBD) é um composto derivado da Cannabis sativa que não apresenta os efeitos psicotomiméticos e os sintomas colaterais geralmente provocados pela utilização da planta e que são, em sua maioria, atribuídos ao delta-9-tetrahidrocanabinol (THC). Recentemente os estudos a respeito da participação do sistema endocanabinóide em diversos estados fisiológicos e, também em transtornos psiquiátricos, apontam o uso terapêutico de canabinóides como uma estratégia promissora para o controle e prevenção de alguns sintomas ligados a transtornos psicóticos. O perfil antipsicótico do CBD já foi comprovado em modelos experimentais e até em análises clínicas, indicando que esse composto é capaz de prevenir estados psicóticos transitórios, provocados tanto pelo THC quanto pela ketamina, em modelos de psicose induzida. O objetivo deste trabalho foi incrementar as informações já existentes sobre o perfil antipsicótico proposto para o CBD, porém, em três tipos de tarefas comportamentais em roedores, que representam três classes de sintomas do tipo psicóticos que se assemelham aos sintomas da esquizofrenia: atividade locomotora, inibição pré-pulso do reflexo de sobressalto (PPI) e teste de interação social. No modelo utilizado, a S(+)-ketamina (KET) é eficaz na indução de comportamentos que representem sintomas do tipo psicóticos - provocou hiperlocomoção, déficit no filtro sensório-motor e prejuízo no comportamento social. Esses são foram reduzidos quando realizado pré-tratamento com clozapina, com exceção do teste de interação social. Os efeitos do CBD são de acordo com o que é descrito na literatura, apresentando uma curva em U farmacológica característica e diferentes efeitos 6 de acordo com a dose empregada. A análise no monitor de atividades indica que o pré- tratamento com CBD na dose de 30 mg/kg previne a hiperlocomoção induzida por KET, contrastando com o pré-tratamento com CBD na dose de 60 mg/kg, que provoca o aumento do comportamento exploratório após a administração de KET. No PPI, o CBD na dose de 30 mg/kg previne o déficit provocado pela administração de KET, demonstrando-se eficaz para o tratamento de prejuízos cognitivos que acompanham as psicoses; e aumenta o reflexo de sobressalto quando associado a KET. Porém, no teste de interação social, não foram detectadas diferenças significativas. Portanto, com esses resultados, demonstrou-se que o CBD pode ser realmente efetivo para o tratamento de determinados sintomas dos transtornos psicóticos, assim como indicado em alguns trabalhos já desenvolvidos. / Schizophrenia is a psychiatric disorder of significant importance for research in health care, however, despite being the target of numerous clinical and basic studies, there are still many doubts raised about its etiology, pathophysiology and treatment. In recent years, schizophrenia hypotheses that relate to changes in neurotransmitter systems have been very relevant. Currently, the glutamatergic hypothesis complements the dopaminergic, since blockade of NMDA glutamate receptors induces psychotic symptoms in healthy individuals and exacerbate them in patients with schizophrenia, suggesting that a hipofuncional state of these receptors may cause secondary changes in other neurotransmitter systems, leading to positive and negative symptoms and also to cognitive deficits of the disease. Cannabidiol (CBD) is a compound derived from Cannabis sativa that does not show neither the psychotomimetic effects nor side effect symptoms typically caused by the plant use, which are mostly attributed to delta-9-tetrahydrocannabinol (THC). Recently studies about the involvement of the endocannabinoid system in various physiological states and also in psychiatric disorders, suggest the therapeutic use of cannabinoids as a promising strategy for the prevention and control of some symptoms linked, for example, to anxiety, epilepsy and psychotic disorders. The antipsychotic profile of CBD has been confirmed in experimental 7 models and even in clinical trials, indicating that this compound is capable of preventing transient psychotic states caused both by THC and S (+)-ketamine (KET) in psychosis-induced models. The objective of this study was to enhance the existing information on the antipsychotic profile proposed for the CBD, however, three types of behavioral tasks were made for the analysis of three classes of psychotic-like symptoms in rodents, which are manifested through hyperlocomotion (positive symptoms), impairment in social interaction (negative symptoms) and a deficit in sensorimotor gating (cognitive deficits). The effects achieved with CBD are in accordance with the described in literature, a characteristic Ushaped curve and different pharmacological effects according to dose used. The analysis in the open field reveals that animals pretreated with CBD at a dose of 30 mg/kg shows a reduction in KET-induced hyperlocomotion, contrasting with the effects of CBD at a dose of 60 mg/kg, that enhances exploratory behavior after KET injection. In the PPI, the CBD at a dose of 30 mg/kg prevented the deficit caused by KET administration, showing effectiveness for the treatment of cognitive impairments that accompany psychosis; and enhances startle reflex when associated to KET. Therefore, with these results, it was demonstrated that CBD may be really effective for the treatment of certain symptoms of psychotic disorders, in accordance to some already developed studies.

The contamination of seafood with methylmercury (MeHg) is a global health issue, as MeHg is a well known neurotoxin. Since dietary nutrients may interact with MeHg toxicity, and oxidative stress is one of the primary mechanisms underlying MeHg neurotoxicity, we characterized dietary antioxidant-MeHg interactions. Firstly, we used an ethnobotanical study to confirm the antioxidant activity of Northern Labrador Tea, Rhododendron tomentosum ssp. subarcticum (Tea), for the Canadian Inuit, a population with elevated MeHg exposure. Secondly, we determined the ability of Tea to ameliorate MeHg-induced toxicity in a rat perinatal exposure study. MeHg exposure (2 mg/KgBW/d) was associated with perturbed development and behaviour, elevated brain N-methyl-D-aspartate receptors, and serum lipid peroxidation. Surprisingly, Tea co-exposure (100 mg/KgBW/d) modulated MeHg’s effects on brain NMDA-R levels and lipid peroxidation, but also increased mercury serum concentrations. Thirdly, using a toxicogenomics approach we determined that MeHg exposure caused the down-regulation of Nr4a2 and its protein product Nurr1. These novel MeHg targets are implicated in developmental learning functions and were corrected with MeHg + Tea co-exposure. Lastly, we conducted a risk assessment survey and cross-sectional dietary epidemiology study in Costa Rica to further investigate dietary nutrient-MeHg interactions. Costa Rica is a Central American country with multiple sources of Hg and a high per capital fish consumption. Here, 5 of the 14 populations we studied exceeded the recommended MeHg provisional tolerable daily intake (pTDI) of 0.2 µg/KgBW/d. In Heredia the pTDI was exceeded by 34% of woman participants, primarily associated with canned tuna consumption. Interestingly, we detected that Hg body burden was significantly reduced by the consumption of antioxidant-rich dietary items. Considering our collective results, we hypothesized that MeHg toxicokinetics may be altered by dietary nutrients at the site of intestinal absorption from the disruption of gut flora, or at the site of cellular demethylation in tissues from the improvement of cellular redox state. The interaction of dietary nutrients on MeHg outcomes has a large impact on risk assessment and may provide a public health approach for managing the risk associated with MeHg exposure without reducing local fish consumption.

Excitotoxicity, a major hallmark of neurodegeneration associated with cerebral ischemia, is a result of accumulation of extracellular glutamate. This excess glutamate leads to hyperactivation of glutamate receptors such as the N-methyl-D-asparate (NMDA) receptors (NMDARs) following the activation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor (AMPARs). Excessive activation of NMDARs causes an influx of calcium, which can eventually activate apoptotic pathways and lead to death of neurons. Regulation of NMDAR subunit composition, localization, surface expression, and activity can balance cell survival via activation of either pro-death or pro-survival pathways after a course of an ischemic insult. Specifically, phosphorylation of different NMDAR subunits defines their activity and downstream signaling pathways. NMDARs are phosphorylated by multiple kinases and dephosphorylated by different phosphatases. Besides phosphatases and kinases, per se, phosphorylation of synaptic proteins that regulate kinase or phosphatase targeting and activity also mediate NMDAR phosphorylation. Spinophilin, a major synaptic scaffolding and protein phosphatase 1 (PP1) targeting protein, mediates substrate phosphorylation via its ability to bind PP1. Our studies focus on delineating the role of spinophilin in the regulation of phosphorylation and function of the GluN2B subunit of the NMDA receptor as well as the role of spinophilin in modulating glutamate-induced neurotoxicity. Interestingly, our data demonstrate that spinophilin sequesters PP1 away from GluN2B thereby enhancing phosphorylation of GluN2B at Ser-1284. These changes impact GluN2B protein interactions, subcellular localization, and surface expression, leading to alterations in the amount of calcium entering the neuron via GluN2B-containing NMDARs. Our data show that spinophilin biphasically regulates GluN2B function. Specifically, Ser-1284 phosphorylation enhances calcium influx through GluN2B containing NMDA receptors, but spinophilin leads to dramatic decreases in the surface expression of the receptor independent of Ser-1284 phosphorylation. Moreover, in spinophilin knockout mice, we observe less PP1 binding to GluN2B and less phosphorylation of Ser-1284, but more surface expression of GluN2B and greater levels of caspase activity. Together, these observations suggest a potential neuroprotective role for spinophilin by decreasing GluN2B-containing NMDA receptor-dependent surface expression and thereby decreasing intracellular calcium and neuronal cell death.

N-methyl-D-aspartate (NMDA) receptors are a class of ionotropic glutamate receptors, involved in excitatory synaptic transmission, synaptic plasticity and excitotoxicity. They form heterotetrameric complexes composed of GluN1, GluN2A-D and/or GluN3A-B subunits that are activated by glutamate and glycine. Previous reports showed that different subunits of NMDA receptors, especially the GluN2 subunits, confer different functional and pharmacological properties on the receptor complexes. However, the subunit-dependent differences in the regulation of intracellular processing and transport of NMDA receptor subtypes has not been clearly elucidated. The aim of this work was to clarify the mechanisms of regulation of the NMDA receptor transport. In our experiments we performed immunocytochemistry of receptors on heterologous COS-7 cells and cultured cerebellar granule cells (CGC), both expressing recombinant NMDA receptors. The results of my work show that the transport of NMDA receptors is regulated by presence of GluN2A and GluN2B subunits. Our results further showed that transport of the GluN1/GluN2C receptors is regulated by three specific areas of the GluN2C subunit: i) the A2 segment within the amino- terminal domain, ii.) the M3 domain, and iii.) the proximal part of the C-terminus containing the...

N-methyl-D-aspartate (NMDA) receptors are glutamate-gated calcium permeable ion channels that play a key role in excitatory synaptic transmission and plasticity, and their dysfunction underlies several neuropsychiatric disorders. The overactivation of NMDA receptors by tonically increased ambient glutamate can lead to excitotoxicity, associated with various acute and chronic neurological disorders, such as ischemia, Alzheimer and Parkinson's disease, epilepsy or depression. On the opposite, NMDA receptor hypofunction is thought to be implicated in autism, schizophrenia, or intellectual disability. Recent DNA screening for neurological and psychiatric patients revealed numerous mutations in genes encoding for NMDA receptor subunits. The activity of NMDA receptors is influenced by a wide variety of allosteric modulators, including neurosteroids that could both inhibit and potentiate the activity of NMDA receptors, which makes them promising therapeutic targets. In this thesis, we describe new classes of neurosteroid analogues which possess structural modifications at carbons C3 and C17 of the steroidal core, and analogues without D-ring region (perhydrophenanthrenes). We evaluated the structure-activity relationship (SAR) for their modulatory effect on recombinant GluN1/GluN2B receptors. Our results...